Compare ARTL & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARTL | SXTP |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.7M |
| IPO Year | N/A | 2023 |
| Metric | ARTL | SXTP |
|---|---|---|
| Price | $1.84 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $30.00 | $4.40 |
| AVG Volume (30 Days) | ★ 1.3M | 57.4K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,364,945.00 |
| Revenue This Year | N/A | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 202.10 |
| 52 Week Low | $1.52 | $0.85 |
| 52 Week High | $28.60 | $12.45 |
| Indicator | ARTL | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 33.96 | 37.24 |
| Support Level | $1.62 | $0.96 |
| Resistance Level | $1.98 | $1.12 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 69.53 | 42.50 |
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.